Lyme disease: Who should be tested and treated, and how?

Netherlands Journal of Medicine

Volumn 51, Issue 5, 1997, Pages 154-162

  Blaauw, A A M ^a   Rijpkema, S G T ^b   Kuiper, H ^c   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Flevo Hospital   (Netherlands)

Author keywords

Antibiotics; Antimicrobials; Lyme disease

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME AXETIL; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G;

ARTHRITIS; ASEPTIC MENINGITIS; BORRELIA BURGDORFERI; CARDITIS; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FACIAL NERVE PARALYSIS; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; LYME DISEASE; POLYMERASE CHAIN REACTION; SERODIAGNOSIS; SHORT SURVEY; SKIN BIOPSY; TICK BITE;

EID: 0031456332     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(97)00064-8     Document Type: Article

References (63)

1. Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis. An epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum 1977;20:7-17.
2. Steere AC. Lyme disease. New Engl 3 Med 1989;321:586-596.
3. Postic D, Assous M, Grimont PAD, Baranton G. Diversity of Borrelia burgdorferi sensu lato evidenced by restriction fragment length polymorphism of rrf(5S)-rrl(23S) intergenic spacer amplicons. Int J Syst Bacteriol 1994;44:743-752.
4. Klempner MS, Noring R, Epstein MP, et al. Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis 1995;171:1258-1265.
5. Fuchs H, Wallich R, Simon MM, Kramer MD, The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmint(ogen) receptor. Proc Natl Acad Sci USA 1994;91:12594-12598.
6. Coleman JL, Sellati TJ, Testa JE, Kew RR, Furie MB, Benach JL. Borrelia burgdorferi binds plasminogen, resulting in enhanced penetration of endothelial monolayers. Infect Immun 1995,63:2478-2484,
7. Lim LCL, England DM, Glowacki MJ, Duchatcau BK, Schell RF. Involvement of CD4+ lymphocytes in induction of severe destructive Lyme arthritis in inbred LSH hamsters. Infect Immun 1995;63:4818-4825.
8. Keane-Myers A, Nickell SP. Role of IL-4 and IFN-gamma in modulation of immunity to Borrelia burgdorferi in mice. J Immunol 1995;155:2020-2028.
9. Matyniak JE, Reiner SL. T helper phenotype and genetic susceptibility in experimental Lyme disease. J Exp Med 1995;181:1251-1254.
10. Gerber MA, Shapiro ED, Burke GS, Parcetls VJ, Bell GL. Lyme disease in children in southeastern Connecticut. New Engl J Med 1996;335:1270-1274.
11. Berglund J, Eitrem R, Ornstein K, et al. An epidemiologic study of Lyme disease in Southern Sweden. New Engl J Med 1995;333:1319-1324.
12. Halperm JJ, Logigian EL, Finkel MF, Pearl RA. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Neurology 1996;46:619-627.
13. Steere AC, Taylor E, McHugh GL, Logigian EL. The over-diagnosis of Lyme disease. J Am Med Assoc 1993;269:1812-1816.
14. Blaauw AAM, Bijlsma JWJ. Musculoskelatale klachten vaak ten unrechte aan Lyme-ziekte loegeschreven. Ned Tijdschr Geneeskd 1997;141:474-477.
15. Blaauw AAM, Schuwirth LWT, van der Vleuten CPM, de Rooy MJM, Smits F, van der Linden S. Do general practitioners in the Netherlands recognize Lyme borreliosis?. J Spirochetal Tickborne Dis 1994;3:68-73.
16. Berger BE. Johnson RC, Kodner C, Coleman L. Cultivation of Borrelia burgdurferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 1992;30:359-361.
17. van Dam AP, Kuiper H, Vos K, et al. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme boneliosis. Clin Infect Dis 1993;17:708-717.
18. Maynarelli LA, Miller JN, Anderson JF, Rivere GR. Cross-reactivity of nonspecific treponemal antibody in serologic tests for Lyme disease, J Clin Microbiol 1990;28:1276-1279.
19. Nohlmans MKE, van den Bogaard AEJM, Blaauw AAM, van Boven CPA. Prevalence van Lyme borrcliosis in Nederland. Ned Tijdschr Geneeskd 1991;135:2288-2292.
20. Fahrer H, van der Linden SM, Sauvain MJ, Gern L, Zhioua E, Aesclilimann A. The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk. J Infect Dis 1991;163:305-310.
21. Blaauw AAM, Nohimans MKE, van den Bogaard AEJM, van der Linden S. Diagnostic tools in Lyme borreliosis: clinical history compared with serology. J Clin Epidemiol 1992;11:1229-1236.
22. Kuiper H, de Jongh BM, Nauta AP. et al. Lyme borreliosis in Dutch forestry workers. J Infect 1991;23:279-286.
23. Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J Clin Invest 1986;78:934-939.
24. Wilske BA, Preac-Mursic V, Schierz G, Busch KV. Immunochemical and immunological analysis of European Borrelia burgdarferi strains. Zentralbl Bakteriol Hyg A 1986;263:92-102.
25. Hansen K, Hindersson P, Strandberg Pedersen N. Measurements of antibodies to the Borrelia burgdorferi flagellum improves serodiagnusis in Lyme disease. J Clin Microbiol 1988;26:338-346.
26. Wilske BA, Preac-Mursic V. Fuchs R, Soutschek E. Immunodominant proteins of Borrelia burgdorferi, the etiological agent of Lyme boneliosis. World J Microbiol Biotechnol 1991;7:130-136.
27. Hansen K. Pu K, Lebech AM. Improved immunoglobulin M serodiagnosis in Lyme borreliosis by using a μ-capture enzyme-linked immunosorbent assay with biotinylated Borrelia burgdorferi flagella. J Clin Microbiol 1991;29:166-173.
28. Schneider T, Lange R, Rönspeck W, Weigelt W, Kölmel HW. Prognostic B-cell epitopes on the flagellar protein of Borrelia burgdorferi. Infect Immun 1992;60:316-319.
29. Rijpkema S, Groen J, Molkenboer M, et al. Serum antibodies to the flagellum of Borrelia burgdorferi measured with an inhibition enzyme-linked immunosorbent assay are diagnostic for Lyme borreliosis. Scrodiagn Immunother 1994;6:61-67.
30. CDC Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme disease. MMWR 1995;44:590-591.
31. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993;167:392-400
32. Engstrom SM, Shoop E, Johnson RC, Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microhiol 1995;33:419-427.
33. Nohlmans, MKE. Lyme borreliosis in the Netherlands. Thesis University of Limburg, 1995, ISBN 90-801844-3-8.
34. Cooke WD, Bartenhagen NH. Seroreactivity to Borrelia burgdorferi antigens in the absence of Lyme disease. J Rheum 1994;21:126-131.
35. Gern L, Leuba Garcia S, Frossard E. Characterization and follow-up of the IgG antibody response against Borrelia burgdorferi using Western blot in a seropositive (ELISA) population from an endemic area. Bull Soc Neuchâteoise Sci Nat 1993:116:5-14.
36. Blaauw, AAM, van Loon, AM, Schellekens, JFP, Bijlsma, JWJ. Clinical evaluation of the two-test approach for Lyme disease. Arth Rheum 1997; 40 suppl. E.
37. Rijpkema SGT, Tazelaar DJ, Molkenboer MJCH, et al. Detection of Borrelia afzelii, Borrelia burgdorferi sensu stricto, Borrelia garinii and group VS116 by PCR in skin biopsies of patients with erythema migrans and acrodermatitis chronica atrophicans. Clin Microbiol Infect 1997;3:1-8.
38. Guy EC, Stanek G. Detection of Borrelia burgdorferi in patients with Lyme disease by the polymerase chain reaction. J Clin Pathol 1991;44:610-611.
39. Schmidt B, Muelleger RR, Stockenhuber C, et al. Detection of Borrtlia burgdorferi-specific DNA in urine specimens from patients with erythema migrans before and after antibiotic therapy. J Clin Microbiol 1996;34:1359-1363.
40. Huppertz HI, Schmidt H, Karch H. Detection of Borretia burgdorferi by nested polymerase chain reaction in cerebrospinal fluid and urine of children with neuroborreliosis. Eur J Pediatr 1993;61:2774-2779.
41. Lebech AM, Hansen K. Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluids from patients with early and late Lyme neuroborreliosis by polymerase chain reaction. J Clin Microbiol 1992;30:1646-1653.
42. Goodman JL, Jurkovich P, Kramer JM, Johnson RC. Molecular detection of Borrelia burgdorferi in the urine of patients with active Lyme disease. Infect Immun 1991;59:269-278.
43. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. New Engl J Med 1994;330:229-234.
44. Karch H, Huppertz HI, Böhme M, Schmidt H, Wiebecke D, Schwarzkopf A. Demonstration of Borrelia burgdorferi DNA in urine samples from healthy individuals whose sera contain Borrelia burgdorferi specific antibodies. J Clin Microbiol 1994;32:2312-2314.
45. Demaerschalck I, Ben Massoud A, de Kesel M, et al. Simultaneous presence of different Borrelia burgdorferi sensu lato genospecies in biological fluids of Lyme disease patients. J Clin Microbiol 1995;33:602-608.
46. Hansen K, Lebech AM. Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferi-specific immunoglobulin G, A, and M. Ann Neurol 1991;30:197-205.
47. Luger SW, Paparone P, Wormser GP, et al. Comparison of Cefuroxime Axetil and Doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 199:5;39:661-667.
48. Luft BJ, Dattwyler RJ, Johnson RC. et al. Azithromycin compared with Amoxycillin in the treatment of erythema migrans. Ann Intern Med 1996;124:785-791.
49. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone campared with doxycycline for the treatment of acute dissiminated Lyme disease. New Engl J Med 1997;337:289-294.
50. Dattwyler, RJ, Halperin, JJ, Volkmau, DJ, Luft, BJ. Treatment of late Lyme disease. Lancet 1988;1191-1193.
51. Ettcstad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995;171:356-361.
52. Kartsson M, Hammers-Berggren S, Liudquist L, Stienistedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neurohorreliosis. Neurology 1994;44:1203-1207.
53. Sigal LH. Early disseminated Lyme disease: cardiac manifestations. Am J Med 1995;98(4A):25S-29S.
54. Steere AC, Levin RE, Molloy, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994;37:878-888.
55. Steere AC. Musculoskeletal manifestations of Lyme disease. Am J Med 1995;98(4A):44S-51S.
56. Eckman MH, Steere AC, Kalish RA, Pauker SG. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. New Engl J Med 1997;337:357-363.
57. Lengl-Janßen B, Strauss AF, Steere AC, Kamradt Th. The T helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-responsive Lyme arthritis. J Exp Med 1994;180:2069-2078.
58. Cooper JD, Schoen RT, Malawista SE. Treatment of asymptomatic, retrospectively diagnosed, Lyme disease: comment on the report by Christian. Arthritis Rheum 1992;35:1637-1638. letter.
59. Sigal LH. Persisting complaints attributed to Lyme disease: possible mechanisms and implications for management. Am J Med 1994;96:365-374.
60. Sigal LH. Pseudo-Lyme disease. Bull Rheum Dis 1995;44:1-3.
61. Blaauw AAM, Dijkmans BAC, Bouma PAD, van der Linden S. Rational diagnosis and treatment in unclassified arthritis: how clinical data may guide requests for Lyme serology and antibiotic treatment. Ann Rheum Dis 1993;52:206-210.
62. Lightfoot RW, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatique and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Ann Intern Med 1993;119:503-509.
63. Nowakowski J, Schwanz I, Nadelman RB, Livens D, Wormser GP, Culture-confirmed infection and reinfection with B. burgdorferi. Ann Intern Med 1997;127:130-132.